A Phase 3 interventional study of INCA033989 and Best Available Treatment in Essential Thrombocythemia, sponsored by Incyte Corporation. Recruiting at 196 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Thrombocythemia, Essential with a site in United States — 17 open to participants now, 31 under way, 6 of them phase 3. Thrombocythemia, Essential · United States.
Among the 149 studies in Thrombocythemia, Essential with a site in United States, this one is the 2nd largest by planned enrollment of the 120 interventional ones that give a count, is one of 3 that started in 2026, is one of 17 in phase 3, reaches primary completion later than 22 of the 30 other live ones, and was the 148th registered.
229 studies on the registry are indexed under Thrombocythemia, Essential; 37 are open to participants now.
Browse Thrombocythemia, Essential studies →17 of the 149 studies in Thrombocythemia, Essential with a site in United States are open now. Recruiting first, the newest first:
Damora Therapeutics · Sites in United States, Australia
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
MPN Research Foundation · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Thrombocythemia, Essential studies recruiting now, 29 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 66 · Phase 3 18
First in 1992; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 426 is above the median of 53 across 168 interventional studies indexed under Thrombocythemia, Essential.
Median enrollment 45 across the 120 interventional studies, 592 across the 13 observational. Of the 113 that completed or were terminated, 36 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 149 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 8 studies filed under Thrombocythemia, Essential — fewer than ten, so there is no comparison to draw.
10 of the studies in Thrombocythemia, Essential with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079879Phase 3Merck Sharp & Dohme LLCA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | 2027-07-14 |
| NCT06456346Phase 3Merck Sharp & Dohme LLCBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | 2027-09-28 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT06063486University of Southern CaliforniaCurcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 149 studies in Thrombocythemia, Essential with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered intravenous (IV) in accordance with the protocol-defined requirements.
Drug: INCA033989
Best Available Therapy (BAT) will be selected by the investigator.
Drug: Best Available Treatment
Administered intravenous (IV) in accordance with the protocol-defined requirements.
Best Available Therapy (BAT) will be selected by the investigator.
Also known as: BAT could include:, • HU, • ANA, • PEG interferon alfa-2a, • Ropeginterferon alfa-2b
Durable clinicohematologic response (DCR)
Normalization of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.
Time frame: Week 24
Reduction from baseline in calreticulin exon 9 frameshift mutation(s) (mutCLAR) variant allele frequency (VAF)
Reduction in mutCALR VAF as defined in the protocol.
Time frame: Week 24
Durable clinicohematologic response (DCR)
Normalization of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.
Time frame: Week 48
Durable partial clinicohematologic response (DPR)
Improvement of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.
Time frame: Week 24
Durable partial clinicohematologic response (DPR)
Improvement of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.
Time frame: Week 48
Longest duration of complete hematologic response (CHR)
Longest time from documented CHR until the loss of CHR as defined in the protocol.
Time frame: Up to Week 48
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Defined as any adverse event occurring after the first dose of study drug until up to 60 days after the last dose of study drug.
Time frame: Up to Week 48 and 60 days after last dose
TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment
TEAEs leading to dose interruptions, dose reductions or discontinuation of study treatment.
Time frame: Up to Week 48 and 60 days after last dose
Number of participants with a reduction in mutCALR VAF
Number of participants with a reduction in mutCALR VAF as defined in the protocol.
Time frame: Week 24 and Week 48
Molecular response
Overall reduction in mutCALR VAF as defined in the protocol.
Time frame: Week 24 and Week 48
Change from baseline in Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total symptom score (TSS)
Defined as the proportion of participants who achieve a protocol defined reduction in TSS.
Time frame: Up to Week 48
Change from baseline in Brief Fatigue Inventory (BFI) fatigue score
The BFI is a 9 item scored from 0 (no fatigue) -10 (as bad as you can imagine), items are averaged with total score from 0-10, with higher score indicating more fatigue.
Time frame: Up to Week 48
Patient Global Impression of Change (PGIC) score
The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.
Time frame: Up to Week 48
Showing the first 100 of 196 sites across 22 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Started Sep 2026 (actual). Primary completion is estimated for Jun 2029, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-mutant Calreticulin Monoclonal Antibody INCA033989